Ezetimibe Deprotected Impurity is a synthetically derived byproduct arising from the deprotection step in Ezetimibe synthesis, characterized by an indole core linked to a tetrahydrofuran ring via an ethenyl bridge, with a deprotected amino group at the 2-position of the indole. Its structure retains the fluorobenzyl substituent of the parent drug but features an unmasked primary amine, distinguishing it from the protected intermediate. This impurity is critical for validating deprotection efficiency in synthetic pathways and serves as an HPLC reference standard for quantifying residual deprotected species in Ezetimibe active pharmaceutical ingredient batches.
On RequestC1[C@@H](N(C(=O)O1)C(=O)[C@H](CC[C@@H](C2=CC=C(C=C2)F)O)[C@@H](C3=CC=C(C=C3)O)NC4=CC=C(C=C4)F)C5=CC=CC=C5
InChI=1S/C33H30F2N2O5/c34-24-10-6-22(7-11-24)30(39)19-18-28(32(40)37-29(20-42-33(37)41)21-4-2-1-3-5-21)31(23-8-16-27(38)17-9-23)36-26-14-12-25(35)13-15-26/h1-17,28-31,36,38-39H,18-20H2/t28-,29-,30+,31-/m1/s1
WYMDQBFNYMAMNK-LTXXGDHTSA-N